INCYTE
Incyte 2014 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology.

News
Incyte and Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis
Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings
Jakafi® (ruxolitinib)
IncyteCARES
Connecting to Access, Reimbursement, Education and Support
To learn more, click here